Register
Home Quizzes Quiz Detail
Practice Quiz

Arab Board Oncology Clinical Practice Questions - Arab Board Medical Oncology Final Practical Clinical Examination - الامتحان النهائي العملي لاختصاص طب الأورام (ABHS) Exam

100 questions 5.0 rating Mobile friendly
$69.00

Unlock the full practice quiz

Get complete access to the questions, explanations and printable quiz resources.

Full access: unlock all quiz questions and explanations.
Printable review: access the full quiz PDF with correct answers after purchase.

About this Exam

Prepare with the Arab Board Oncology Clinical Practice Questions - Arab Board Medical Oncology Final Practical Clinical Examination - الامتحان النهائي العملي لاختصاص طب الأورام (ABHS) Exam practice quiz. This question bank includes 100 questions covering year-old, therapy, standard, woman, and carcinoma. Use it to review important concepts, identify knowledge gaps, and build confidence for the related exam, course, or assessment.

Sample Questions

Question 1
A 52-year-old postmenopausal woman undergoes lumpectomy and sentinel lymph node biopsy for a 2.1 cm invasive ductal carcinoma. Pathology reveals grade 2 carcinoma, ER 95%, PR 80%, HER2-negative (IHC 0), and 1 sentinel lymph node containing a 1.2 mm micrometastasis (pN1mi). Genomic profiling reveals a 21-gene Recurrence Score (RS) of 14. What is the most appropriate adjuvant systemic therapy?
Adjuvant endocrine therapy alone with an aromatase inhibitor
Adjuvant dose-dense AC followed by paclitaxel plus endocrine therapy
Adjuvant TC (docetaxel and cyclophosphamide) plus endocrine therapy
Adjuvant ovarian function suppression plus tamoxifen
Question 2
A 45-year-old premenopausal woman with clinical stage IIA (cT2N0M0) HER2-positive (IHC 3+), ER-negative breast cancer completes 6 cycles of neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, and pertuzumab). She undergoes breast-conserving surgery, and final surgical pathology reveals a 1.2 cm residual invasive carcinoma in the breast with negative margins and clear lymph nodes (ypT1c ypN0). What is the preferred adjuvant HER2-targeted therapy?
Trastuzumab emtansine (T-DM1) for 14 cycles
Trastuzumab plus pertuzumab to complete 1 full year
Trastuzumab monotherapy to complete 1 full year
Trastuzumab deruxtecan (T-DXd) for 8 cycles
Question 3
A 38-year-old woman presents with a 3.5 cm palpable mass in the left breast and ipsilateral mobile axillary lymphadenopathy. Core biopsy confirms grade 3 invasive ductal carcinoma, ER 0%, PR 0%, HER2-negative (triple-negative breast cancer). Staging CT and bone scan show no distant metastases (cT2N1M0). What is the standard neoadjuvant systemic therapy regimen?
Pembrolizumab combined with carboplatin and paclitaxel, followed by pembrolizumab with doxorubicin and cyclophosphamide
Dose-dense AC followed by weekly paclitaxel without immunotherapy
Docetaxel plus cyclophosphamide (TC) for 6 cycles
Cisplatin plus gemcitabine for 4 cycles
Question 4
A 60-year-old postmenopausal woman presents with newly diagnosed de novo metastatic invasive ductal carcinoma of the breast with multiple asymptomatic osteolytic bone metastases and two small asymptomatic liver lesions. Biopsy confirms ER 90%, PR 70%, and HER2 IHC 1+ (HER2-negative). She has no visceral crisis and an ECOG performance status of 1. What is the preferred first-line systemic therapy?
An aromatase inhibitor (e.g., letrozole) plus a CDK4/6 inhibitor (e.g., ribociclib, abemaciclib, or palbociclib)
Single-agent chemotherapy with capecitabine
Combination chemotherapy with doxorubicin and cyclophosphamide (AC)
Tamoxifen monotherapy
Question 5
A 56-year-old woman with metastatic ER-positive, HER2-negative breast cancer experiences disease progression after 24 months on first-line letrozole plus palbociclib. Circulating tumor DNA (ctDNA) next-generation sequencing identifies an activating ESR1 mutation (Y537S). The tumor is PIK3CA wild-type and BRCA1/2 wild-type. What is the most appropriate next-line targeted endocrine therapy?
Elacestrant oral monotherapy
Alpelisib plus fulvestrant
Olaparib monotherapy
Re-challenge with letrozole plus anastrozole

Ready to test your knowledge?

Buy Now to Access

Additional Information

Arab Board Oncology Clinical Practice Questions - Arab Board Medical Oncology Final Practical Clinical Examination - الامتحان النهائي العملي لاختصاص طب الأورام (ABHS) Exam

This practice set contains 100 questions from the matching question bank and focuses on year-old, therapy, standard, woman, and carcinoma. Work through each question carefully, review the provided solutions, and revisit topics that need more study before your next attempt.

This is an independent study resource intended for practice and review; it is not an official examination or an endorsement by any organization named in the title.

Related Quizzes

10th Brigade Engineer Battalion (10BEB) Board Practice Exam
50 Qs  |  0 Min
1-67 AR Death Dealers Board Practice Test
100 Qs  |  0 Min
1‑502 NCO and Soldier of the Month Board Practice Exam
100 Qs  |  0 Min
Ultimate Architect Registration Examination ARE Practice Exam
30 Qs  |  0 Min
Architectural Planning Board Practice Exam
10 Qs  |  0 Min

Frequently Asked Questions

This quiz contains a total of 100 practice questions carefully selected to test your knowledge on this subject.
Yes, you will have exactly 0 minutes to complete the exam. A countdown timer will be visible once you start.
Yes, you can retake this practice test as many times as you need. The questions and options may be randomized on subsequent attempts to ensure comprehensive learning.

Reviews

5.0

Based on 0 reviews

Leave a Review

No reviews yet. Be the first to review!